Insulet Corporation (NASDAQ:PODD) Position Increased by Whalen Wealth Management Inc.

Whalen Wealth Management Inc. grew its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 222.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,179 shares of the medical instruments supplier's stock after acquiring an additional 2,193 shares during the quarter. Whalen Wealth Management Inc.'s holdings in Insulet were worth $835,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PODD. Horizon Investments LLC lifted its holdings in shares of Insulet by 3.1% during the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock valued at $362,000 after acquiring an additional 42 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its position in Insulet by 2.3% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock valued at $552,000 after purchasing an additional 48 shares during the period. Steward Partners Investment Advisory LLC lifted its stake in shares of Insulet by 5.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier's stock worth $274,000 after purchasing an additional 50 shares in the last quarter. Sequoia Financial Advisors LLC boosted its position in shares of Insulet by 2.4% in the fourth quarter. Sequoia Financial Advisors LLC now owns 2,170 shares of the medical instruments supplier's stock worth $566,000 after buying an additional 50 shares during the period. Finally, Quadrant Capital Group LLC boosted its position in shares of Insulet by 4.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,092 shares of the medical instruments supplier's stock worth $285,000 after buying an additional 51 shares during the period.

Wall Street Analyst Weigh In

PODD has been the topic of several analyst reports. Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Royal Bank Of Canada assumed coverage on shares of Insulet in a research note on Thursday, March 6th. They set an "outperform" rating and a $340.00 price objective on the stock. Wall Street Zen cut shares of Insulet from a "buy" rating to a "hold" rating in a research report on Saturday, June 14th. Oppenheimer upped their target price on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Finally, The Goldman Sachs Group assumed coverage on shares of Insulet in a research note on Friday, May 30th. They set a "buy" rating and a $380.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, Insulet currently has a consensus rating of "Moderate Buy" and an average target price of $321.00.

Insider Buying and Selling at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president now directly owns 23,180 shares in the company, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.39% of the stock is owned by insiders.

Insulet Stock Up 1.2%

NASDAQ:PODD traded up $3.60 during mid-day trading on Thursday, reaching $309.83. The stock had a trading volume of 628,466 shares, compared to its average volume of 714,019. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.47 and a quick ratio of 3.63. The company has a market capitalization of $21.81 billion, a price-to-earnings ratio of 55.72, a price-to-earnings-growth ratio of 2.73 and a beta of 1.37. Insulet Corporation has a 1-year low of $173.00 and a 1-year high of $329.33. The stock's 50 day simple moving average is $296.37 and its two-hundred day simple moving average is $277.35.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The company had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. During the same quarter last year, the firm earned $0.73 EPS. The business's revenue was up 28.8% on a year-over-year basis. Equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.